Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer

Dong, 1996, . Prostate cancerbiology of metastasis and its clinical implications., World J Urol, 14, 182, 10.1007/BF00186898

Haseman, 2000, Capromab pendetide imaging of prostate cancer., Cancer Biother Radiopharm, 15, 131, 10.1089/cbr.2000.15.131

Apolo, 2008, Novel tracers and their development for the imaging of metastatic prostate cancer., J Nucl Med, 49, 2031, 10.2967/jnumed.108.050658

Gillies, 2008, Causes and consequences of increased glucose metabolism of cancers., J Nucl Med, 49, 24S, 10.2967/jnumed.107.047258

Jadvar, 2009, Molecular imaging of prostate cancer with F-18-fluorodeoxyglucose PET., Nat Rev Urol, 6, 317, 10.1038/nrurol.2009.81

Iagaru, 2012, . Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PETCT, and (18)F FDG PETCT for detection of skeletal metastases., Mol Imaging Biol, 14, 252, 10.1007/s11307-011-0486-2

Even-Sapir, 2006, . The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PETCT., J Nucl Med, 47, 287

Cookson, 2007, . Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes., J Urol, 177, 540, 10.1016/j.juro.2006.10.097

Roach, 2006, . Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference., Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029

Scher, 2008, . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group., J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487

Segall, 2010, . SNM guideline for sodium 18F-fluoride PETCT bone scan 1.0., J Nucl Med, 51, 1813, 10.2967/jnumed.110.082263

Carroll, 2001, Rising PSA after a radical treatment., Eur Urol, 40, 9, 10.1159/000049879

Picchio, 2011, . The role of choline positron emission tomographycomputed tomography in the management of patienst with prostate-specific antigen progression after radical treatment of prostate cancer., Eur Urol, 59, 51, 10.1016/j.eururo.2010.09.004

Schoder, 2005, . 2-18Ffluoro-2-deoxyglucose positron emission tomography for detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy., Clin Cancer Res, 11, 4761, 10.1158/1078-0432.CCR-05-0249

Chang, 2003, . Detecting metastatic pelvic lymph nodes by (18)F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer., Urol Int, 70, 311, 10.1159/000070141

Gomez, 2004, Kim SS, et al.., Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated BJU Int, 94, 299

Cook, 2011, . The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer., Eur J Nucl Med Mol Imaging, 38, 7, 10.1007/s00259-010-1576-0

Iagaru, 2009, . Novel strategy for a cocktail 18F-fluoride and 18F-FDG PETCT scan for evaluation of malignancy: results of the pilot-phase study., J Nucl Med, 50, 501, 10.2967/jnumed.108.058339

Wade, 2006, . Flare response in 18F-fluoride ion PET bone scanning., AJR Am J Roentgenol, 186, 1783, 10.2214/AJR.05.0225

Basu, 2010, Combined 18F-FDG and fluoride approach in PETCT imaging: is there a clinical future letter., J Nucl Med, 51, 165, 10.2967/jnumed.109.066860